127 related articles for article (PubMed ID: 10663383)
1. NAD(P)H quinone oxidoreductase 1 codon 609 polymorphism and its association to colorectal cancer.
Harth V; Donat S; Ko Y; Abel J; Vetter H; Brüning T
Arch Toxicol; 2000 Jan; 73(10-11):528-31. PubMed ID: 10663383
[TBL] [Abstract][Full Text] [Related]
2. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese.
Hamajima N; Matsuo K; Iwata H; Shinoda M; Yamamura Y; Kato T; Hatooka S; Mitsudomi T; Suyama M; Kagami Y; Ogura M; Ando M; Sugimura Y; Tajima K
Int J Clin Oncol; 2002 Apr; 7(2):103-8. PubMed ID: 12018106
[TBL] [Abstract][Full Text] [Related]
3. NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors.
Lafuente MJ; Casterad X; Trias M; Ascaso C; Molina R; Ballesta A; Zheng S; Wiencke JK; Lafuente A
Carcinogenesis; 2000 Oct; 21(10):1813-9. PubMed ID: 11023538
[TBL] [Abstract][Full Text] [Related]
4. NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and colorectal cancer predisposition in the ethnic Kashmiri population.
Sameer AS; Shah ZA; Syeed N; Rasool R; Afroze D; Siddiqi MA
Asian Pac J Cancer Prev; 2010; 11(1):209-13. PubMed ID: 20593958
[TBL] [Abstract][Full Text] [Related]
5. Role of epoxide hydrolase, NAD(P)H:quinone oxidoreductase, cytochrome P450 2E1 or alcohol dehydrogenase genotypes in susceptibility to colorectal cancer.
van der Logt EM; Bergevoet SM; Roelofs HM; Te Morsche RH; Dijk Yv; Wobbes T; Nagengast FM; Peters WH
Mutat Res; 2006 Jan; 593(1-2):39-49. PubMed ID: 16039674
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms of NAD(P)H quinone oxidoreductase, CYP1A1 and microsomal epoxide hydrolase and lung cancer risk in Nanjing, China.
Yin L; Pu Y; Liu TY; Tung YH; Chen KW; Lin P
Lung Cancer; 2001; 33(2-3):133-41. PubMed ID: 11551408
[TBL] [Abstract][Full Text] [Related]
7. Analysis of NQO1, GSTP1, and MnSOD genetic polymorphisms on lung cancer risk in Taiwan.
Lin P; Hsueh YM; Ko JL; Liang YF; Tsai KJ; Chen CY
Lung Cancer; 2003 May; 40(2):123-9. PubMed ID: 12711112
[TBL] [Abstract][Full Text] [Related]
8. Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking.
Rosvold EA; McGlynn KA; Lustbader ED; Buetow KH
Pharmacogenetics; 1995 Aug; 5(4):199-206. PubMed ID: 8528266
[TBL] [Abstract][Full Text] [Related]
9. NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis.
Chao C; Zhang ZF; Berthiller J; Boffetta P; Hashibe M
Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):979-87. PubMed ID: 16702380
[TBL] [Abstract][Full Text] [Related]
10. NAD(P)H: quinone oxidoreductase polymorphism and lung cancer in Taiwan.
Lin P; Wang HJ; Lee H; Lee HS; Wang SL; Hsueh YM; Tsai KJ; Chen CY
J Toxicol Environ Health A; 1999 Oct; 58(4):187-97. PubMed ID: 10591487
[TBL] [Abstract][Full Text] [Related]
11. Association between NAD(P)H: quinone oxidoreductase 1 (NQ01) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract.
Sarbia M; Bitzer M; Siegel D; Ross D; Schulz WA; Zotz RB; Kiel S; Geddert H; Kandemir Y; Walter A; Willers R; Gabbert HE
Int J Cancer; 2003 Nov; 107(3):381-6. PubMed ID: 14506737
[TBL] [Abstract][Full Text] [Related]
12. Increased levels of NAD(P)H: quinone oxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: A potential biomarker of early damage in the pancreas.
Lyn-Cook BD; Yan-Sanders Y; Moore S; Taylor S; Word B; Hammons GJ
Cell Biol Toxicol; 2006 Mar; 22(2):73-80. PubMed ID: 16532285
[TBL] [Abstract][Full Text] [Related]
13. 609 C --> T polymorphism in NAD(P)H:quinone oxidoreductase gene in patients with prostatic adenocarcinoma or benign prostatic hyperplasia.
Steiner M; Hillenbrand M; Borkowsi M; Seiter H; Schuff-Werner P
Cancer Lett; 1999 Jan; 135(1):67-71. PubMed ID: 10077223
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia.
Larson RA; Wang Y; Banerjee M; Wiemels J; Hartford C; Le Beau MM; Smith MT
Blood; 1999 Jul; 94(2):803-7. PubMed ID: 10397748
[TBL] [Abstract][Full Text] [Related]
15. Association between exposure-relevant polymorphisms in CYP1B1, EPHX1, NQO1, GSTM1, GSTP1 and GSTT1 and risk of colorectal cancer in a Czech population.
Hlavata I; Vrana D; Smerhovsky Z; Pardini B; Naccarati A; Vodicka P; Novotny J; Mohelnikova-Duchonova B; Soucek P
Oncol Rep; 2010 Nov; 24(5):1347-53. PubMed ID: 20878130
[TBL] [Abstract][Full Text] [Related]
16. Correlative polymorphism of NAD(P)H: quinone oxidoreductase (NQO1) with telomere shortening in colorectal cancer.
Takagi S; Kinouchi Y; Hiwatashi N; Hirai M; Suzuki S; Takahashi S; Negoro K; Obana N; Shimosegawa T
Anticancer Res; 2002; 22(5):2749-52. PubMed ID: 12529991
[TBL] [Abstract][Full Text] [Related]
17. An association between a NQO1 genetic polymorphism and risk of lung cancer.
Saldivar SJ; Wang Y; Zhao H; Shao L; Lin J; Spitz MR; Wu X
Mutat Res; 2005 Apr; 582(1-2):71-8. PubMed ID: 15781212
[TBL] [Abstract][Full Text] [Related]
18. Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H: quinone oxidoreductase polymorphism.
Wiencke JK; Spitz MR; McMillan A; Kelsey KT
Cancer Epidemiol Biomarkers Prev; 1997 Feb; 6(2):87-92. PubMed ID: 9037558
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in the NAD(P)H: quinone oxidoreductase gene and small cell lung cancer risk in a UK population.
Lewis SJ; Cherry NM; Niven RM; Barber PV; Povey AC
Lung Cancer; 2001 Nov; 34(2):177-83. PubMed ID: 11679176
[TBL] [Abstract][Full Text] [Related]
20. Human NAD(P)H:quinone oxidoreductase 1 (NQO1) and sulfotransferase 1A1 (SULT1A1) polymorphisms and urothelial cancer risk in Taiwan.
Wang YH; Lee YH; Tseng PT; Shen CH; Chiou HY
J Cancer Res Clin Oncol; 2008 Feb; 134(2):203-9. PubMed ID: 17619904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
